Friday, 14 May 2021 - Program Schedule
*all sessions and times are listed in the Eastern Time Zone (EDT) and subject to change. To assist with how to convert times to your specific time zone; just click here.
08:00 - 09:00 |
Exhibit Hall Open │ Visit and meet with exhibitors |
09:00 - 10:30 |
Coagulation and Thromboembolic Issues in Vascular Anomalies |
| Moderators: Gulraiz Chaudry (United States), Cameron Trenor (United States) | |
|
09:00 - 09:25 |
Introductory Clinical Overview │ Shelley Crary (United States) |
|
09:25 - 10:10 |
Case Presentations with Panel Discussion │ Panelists: Shelley Crary (United States), Ludovic Drouet (France), Ahmad Alomari (United States), Steven Fishman (United States) |
|
|
09:25 - 09:40 Case 1: Thromboembolic risk in KTS/CLOVES │ Aparna Annam (United States) |
|
|
09:40 - 09:55 Case 2: Severe Coagulopathy in Lympovenous Malformation │ Dario Teplisky (Argentina) |
|
|
09:55 - 10:10 Case 3: Apixaban to Control Pain in Extensive Lower Limb Venous Malformation │ Matthew Jones (United Kingdom) |
|
10:10 - 10:30 |
Innovations and Future Trends │ Ludovic Drouet (France) |
10:30 - 10:35 |
Break |
10:35 - 12:05 |
Complex AVMs are the Most Challenging Vascular Anomalies to Treat |
| Moderators: Dov Goldenberg (Brazil), Ahmad Alomari (United States) | |
|
10:35 - 10:45 |
Brief Introduction to Types of Arteriovenous Malformations │ Giacomo Coletti (Italy) |
|
10:45 - 11:00 |
Clinical Case on Diagnosis and Treatment Planning │ Tony Penington (Australia) |
|
11:00 - 11:15 |
Clinical Case Solved Exclusively by IR │David Lord (United Kingdom) |
|
11:15 - 11:30 |
Early Approach to AVM and Outcomes │ Xiaoxi Lin (China) |
|
11:30 - 11:45 |
Clinical Case on Surgical Treatment │ Gresham Richter (United States) |
|
11:45 - 12:00 |
Where are we in Pharmacologic Treatment (mTor, MEK inhibitors) │ Laurence Boon (Belgium) |
|
12:00 - 12:05 |
Final Comments |
12:10 - 13:00 |
Exhibit Hall Open │ Visit and meet with exhibitors |
|
|
|
|
12:10 - 12:15 |
Opening Remarks │ Nii Ankrah, MD |
|
12:15 - 12:55 |
The Diagnostic Odyssey of PROS │ Nii Ankrah, MD, Mary Lisha Paul, MD |
|
Case 1: Segmental overgrowth syndrome due to an activating PIK3CA mutation identified in affected muscle tissue by exome sequencing Case 2: Activating PIK3CA somatic mutation in congenital unilateral isolated muscle overgrowth of the upper extremity |
|
|
12:55 - 13:00 |
Break |
|
13:00 - 14:00 |
Then and Now: Moving Toward Targeted Therapeutics │ Nii Ankrah, MD, Mary Lisha Paul, MD |
|
Cases 3 and 4: Molecular heterogeneity of the cerebriform connective tissue nevus in mosaic overgrowth syndromes |
|
|
14:00 - 14:10 |
Questions & Answers |